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Background: Understanding of chronic sequelae development after Campylobacter infection is limited. The
objective of the study was to determine via systematic review and meta-analysis the proportion of Campylobacter
cases that develop chronic sequelae.
Methods: A systematic review of English language articles published prior to July 2011 located using Pubmed,
Agricola, CabDirect, and Food Safety and Technology Abstracts. Observational studies reporting the number of
Campylobacter cases that developed reactive arthritis (ReA), Reiter’s syndrome (RS), haemolytic uraemic syndrome
(HUS), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) ,Guillain Barré syndrome (GBS) or Miller
Fisher syndrome (MFS) were included. Data extraction through independent extraction of articles by four reviewers
(two per article). Random effects meta-analysis was performed and heterogeneity was assessed using the I2 value.
Meta-regression was used to explore the influence of study level variables on heterogeneity.
Results: A total of 31 studies were identified; 20 reported on ReA, 2 reported on RS, 9 reported on IBS, 3 studies
reported on IBD, 8 reported on GBS, 1 reported on MFS and 3 reported on HUS. The proportion of Campylobacter
cases that developed ReA was 2.86% (95% CI 1.40% - 5.61%, I2 = 97.7%), irritable bowel syndrome was 4.01% (95%
CI 1.41% - 10.88%, I2 = 99.2%). Guillain Barré syndrome was 0.07% (95% CI 0.03% - 0.15%, I2 = 72.7%).
Conclusions: A significant number of Campylobacter cases develop a chronic sequela. However, results should be
interpreted with caution due to the high heterogeneity.
Keywords: Foodborne disease, Campylobacter, Systematic literature review, Meta-analysis, Chronic sequelae,
Reactive arthritis, Irritable bowel syndrome, Inflammatory bowel disease, Guillain Barré syndrome, Haemolytic
uraemic syndromeBackground
Globally Campylobacter causes acute gastrointestinal ill-
ness (AGI) in millions of people each year. In the United
States there are a reported 43,698 cases of laboratory con-
firmed Campylobacter spp. annually with estimates of
845,024 (90% CI 337,031 – 1,611,083) cases yearly after
adjusting for under-reporting and under-diagnosis [1]. In
Canada, annual incidence rates of laboratory-confirmed
illness are estimated at 28.4 cases of campylobacteriosis* Correspondence: jkeithlin@gmail.com
1Centre for Public Health and Zoonoses, University of Guelph, Guelph,
Ontario, Canada
2Department of Population Medicine, Ontario Veterinary College, Guelph,
Ontario, Canada
Full list of author information is available at the end of the article
© 2014 Keithlin et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.per 100 000 [2], with actual case counts estimated to be
20–50 times greater than what is laboratory confirmed [3].
Acute complications include bacteraemia, hepatitis, and
pancreatitis. Potential long term health effects, or chronic
sequelae, such as Guillain-Barré syndrome (GBS), reactive
arthritis (ReA) or Reiter’s syndrome (RS), post-infectious
irritable bowel syndrome (IBS) and inflammatory bowel
disease (IBD) have also been associated with infection [4,5].
The most common species of Campylobacter asso-
ciated with human illness are Campylobacter jejuni
and Campylobacter coli [5]. Campylobacter bacteria are
naturally present in digestive tracts of animals such as
swine and poultry [6,7], which present the opportunity
for the bacteria to enter the food system. In addition to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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been linked to travel, contaminated water, direct animal
contact and person to person transmission [8].
Currently, burden of disease estimates that incorporate
the proportion of cases of Campylobacter that develop
severe, long term complications are based on limited in-
formation. For example, in Canada the Ontario Burden
of Infectious Disease Study (ONBOIDS) [9] attempted
to capture the effects of these complications in estimates
for disease burden. However, these estimates were based
on a single study from the Netherlands [10]. From the
United States, updated estimates on the burden associated
with foodborne illness did no capture chronic sequelae
and considered only hospitalization and deaths [1]. Be-
cause of the potential severity and chronic nature of post
infection sequela, to develop true estimates for the burden
of disease for Campylobacter, an accurate estimate for the
number of cases that develop sequela is needed.
Systematic reviews are an established approach to identi-
fying and summarizing a body of literature associated with
a topic area [11]. Meta-analysis (the formal statistical pool-
ing of data from multiple studies), can be used to develop
summary estimates for proportions. Meta-regression al-
lows for the exploration of study level factors that influence
outcomes to assist with the interpretation of these esti-
mates [12]. The usefulness of findings from recent system-
atic reviews for foodborne disease or chronic sequela are
limited as they combine multiple pathogens [13], review
the literature but are not formal systematic reviews [14-16]
or do not present an estimate for the proportion of cases
of Campylobacter that will develop a sequelae [17-19].
Many of the reviews report potential reasons for differ-
ences in estimates for chronic sequelae development be-
tween studies [13,17,18] however exploration of the impact
of these factors on the results reported in studies is limited.
The purpose of the systematic review and meta-
analysis presented here was to develop an estimate for
the proportion of cases of Campylobacter that develop
ReA or RS, GBS or Miller Fisher syndrome (MFS), IBS,
IBD including ulcerative colitis (UC) and Crohn’s disease
(Crohn’s), and haemolytic uraemic syndrome (HUS) and
use meta-regression to explore study level factors that
might contribute to the range of outcomes reported.
Due to the high incidence of infection and potential se-
verity of these long term complications, systematically
determining these proportions from multiple published
estimates would assist in understanding the true burden
of disease associated with Campylobacter.
Methods
Literature search and inclusion–exclusion criteria/data
variables
The following search terms were entered into four
electronic databases (Pubmed, Agricola, CabDirect, andFood Safety and Technology Abstracts) to identify stud-
ies related to chronic sequelae of E. coli O157, Salmon-
ella and Campylobacter; (‘Escherichia coli O157′, or,
‘O157′, ‘VTEC’, ‘STEC’, ‘O157:H7’ or Salmonella or
Campylobacter) and (‘sequel*’, ‘long-term’, ‘long term’,
‘chronic ‘, ‘Guillain*’, ‘HUS’, ‘hemolytic uremic syn-
drome’, ‘haemolytic uraemic syndrome’, ‘hemorrhagic
uremic syndrome’, ‘haemorrhagic uraemic syndrome’,
‘Reiter*’, ’complication*’, ‘arthritis’, ‘irritable bowel syn-
drome’, ‘IBS’, ‘post infectious irritable bowel syndrome’
or ‘inflammatory bowel disease’), without language re-
strictions to identify citations from prior to July 2011.
The systematic review met the criteria outlined in the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) 2009 guidelines. (See Additional
file 1).
Three levels of screening were performed. The first
and second rounds of screening were based on titles and
abstracts only while the third round consisted of a re-
view of full text articles. The first screening was per-
formed by a single reviewer, and excluded references
that did not contain information on the pathogens of
interest or those that were not the study designs of inter-
est (included observational studies only). The second
screening was performed independently by two reviewers
per reference with differences solved by consensus. The
purpose was to restrict the results to more specific patho-
gen subtypes (non-typhoidal Salmonella and Campylobac-
ter species except for Campylobacter pylori) and chronic
sequelae (ReA, RS, IBD, IBS, GBS, MFS, and GBS). Studies
on Campylobacter pylori were excluded as it has been
more recently reclassified as Helicobacter pylori. The
third level of screening identified those publications that
contained the information necessary to answer the re-
search question and data extraction was performed on
those that met the criteria. Screening and data extrac-
tion were performed by four different researchers with
two researchers independently reviewing each full text
article. Conflicts were resolved via discussion to achieve
consensus, with any remaining disagreements resolved
by a third reviewer. Included studies were observational
studies that provided details on the number of cases of
Campylobacter that developed one or more of the
chronic sequelae of interest. Studies reporting the op-
posite relationship, i.e. the number of cases of sequelae
with evidence of past Campylobacter exposure, were
excluded.
Data were extracted on population (years and sea-
son for data collection, country and age range and
gender distribution of Campylobacter cases), Cam-
pylobacter species, study directionality (retrospective
vs. prospective), source of data (surveillance vs. out-
break vs. hospitalized cases), sequelae status prior to
illness with Campylobacter, categories describing both
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sis, the length of time between Campylobacter infec-
tion and sequelae diagnosis (follow-up time) and
outcomes (number of cases of Campylobacter, number
of Campylobacter cases who developed chronic seque-
lae). Prospective studies were those where cases of
Campylobacter were identified and the assessment for
sequelae occurred at a time point in the future.
Retrospective studies were those where both the iden-
tification as a case of Campylobacter and sequelae
diagnosis had already occurred prior to the study ini-
tiation. Diagnosis of Campylobacter was categorized
as confirmed or probable based on the description of
diagnostic methods provided in each publication. Con-
firmed cases of Campylobacter were those where cases
were identified by culture, serology or DNA-based tests
and probable cases were those identified as a case
based on the clinical case definition given in the study.
Diagnoses of the sequelae were categorized as assess-
ment by specialist, physician diagnosed/taken from
medical records or self-reported. Season was classified
as fall (September to November), winter (December
to February), spring (March to May) and summer
(June to August) in the northern hemisphere. In the
southern hemisphere they were classified as fall (March
through May), winter (June through August), spring
(September through November) and summer (December
to February). For the analysis, years of data collection
were classified as decade based on when data collection
began.
After data extraction, studies on outcomes specific to
Campylobacter were identified for inclusion in this re-
view. Each combination of Campylobacter or sequelae
diagnosis was considered as a separate outcome mea-
sure as some studies reported multiple methods of diag-
nosing both Campylobacter ( e.g. a study reporting both
probable and confirmed cases) and the sequelae (e.g. a
study reporting self-reported and specialist confirmed
cases of the sequelae) as well as multiple data sources
(e.g. both outbreak associated and hospitalized cases).
Based on these various classifications, it was possible to
calculate multiple estimates from the same study for
the proportion of cases of Campylobacter that devel-
oped a sequela. Therefore the term “outcome measure”
was used to describe the probability of a case of Cam-
pylobacter developing a chronic sequela for a specific
classification.
Statistical analysis
The primary outcome was the proportion of people with
Campylobacter who developed a specific chronic se-
quela. This was calculated as the number of persons
developing a sequela divided by the total number of
cases of Campylobacter. Standard errors and confidenceintervals for a single proportion were derived. Prior to
analysis adjusted proportions were calculated using a
logit transformation [20].
logit outcome ¼ 1n p
1−p
 
logit standard error ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n p 1−pð Þ
s
Where p is the proportion of people developing the se-
quela and n is the total number of cases of Campylobacter.
All statistical analyses were performed in Stata Version
12 (Statacorp, 2012). Meta-analysis was performed using
a random effects model and the DerSimonian and Laird
method [21]. Heterogeneity was assessed using the I2
value [22]. A count of 0.5 was added to or subtracted
from the number of sequela cases to those reporting a
chronic sequelae outcome of 0% or 100% respectively, to
allow for inclusion in the meta-analysis. Meta-regression
was used to explore potential sources of heterogeneity if
the I2 value was higher than 25% and if greater than 10
outcome measures were present for the sequela of inter-
est [12]. The source of data, the method of diagnosing
Campylobacter, Campylobacter species, method of diag-
nosing the sequelae, country, study directionality, group
size (total number of cases included in study), decade of
data collection and follow-up time were considered as
explanatory variables.
Categorical variables representing group size and fol-
low up time were generated for inclusion in the meta-
regression. Group size was divided into extra small
(n < 100), small (n = 100 to 500), medium (n = 501 to
1000), large (n = 1001 to 9999) and extra-large (n ≥ 10000).
Follow-up time was divided into four categories; less than
a month (30 days), over 30 days to less than 3 months
(90 days), more than 90 days to less than a year, and a year
(365 days) or longer. Study date was classified by the earli-
est decade for data collection. Factors were only included
in the meta-regression if there was variation in the factor
among studies. Univariable analysis was performed to test
for significance. Variables with a p-value of ≤ 0.05 in the
univariable analyses were included in a backwards multi-
variable model and those that remained significant (p ≤
0.05) were further explored with subgroup meta-analysis.
Meta-regression was performed using logit transformed
outcomes and logit transformed within-study standard
errors.
Assessment of reporting of factors related to internal and
external validity
Information on reporting of factors related to internal
validity (risk of bias) and external validity (generalizability)
were extracted to allow for further exploration. Ten
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were study directionality, the source of data, method of
diagnosis for both the pathogen and sequelae, follow-up
time, and reporting the specific criteria used for the seque-
lae diagnosis. The definitions for sequelae diagnosis were
divided into two categories; the method of diagnosis
(physician vs. self-reported vs. other) and whether specific
diagnostic criteria were. Factors related to external validity
were the reporting of relevant population information





Of the 20048 unique citations identified, 860 required
review of the full text article of which 651 were deemed
inapplicable to the research question, 47 studies were
not available in English or French, 24 were inaccessible
(Figure 1). After screening, 147 studies underwent data
extraction of which 31 contained relevant information
on Campylobacter and chronic sequelae.
Reactive arthritis
Study descriptions
Of the 31 studies investigating Campylobacter and chronic
sequelae (Table 1), 20 provided data on ReA. The 20 stud-
ies were from nine countries with almost all (8/9) fromFigure 1 Results from the literature search for studies relating to chro
July 2011.Europe. Sixty percent (12/20) were based on surveillance
data and of those the majority (58%, 7/12) were prospect-
ive in design. Of the five outbreak studies, 60% (3/5) were
waterborne.
Outcome measure
There were 25 outcome measures described, with two
studies [35,43] describing multiple outcome measures
(Table 2). The proportions reported most often for the
development of ReA after Campylobacter infection were
less than 5% (Figure 2). Surveillance based studies
ranged from 13 to 57425 confirmed cases of Campylo-
bacter, with the probability of a case of Campylobacter
developing ReA ranging from 0% to 24%. Outbreak stud-
ies ranged from 42 to 350 cases with the probability of
developing ReA ranging from 0% to 1.5% for confirmed
cases and 0.6% to 2.5% for probable cases. For hospital
based studies case numbers ranged from 41 to 188 cases
with the probability of developing ReA ranging from
1.2% to 5.36%.
Assessment of internal and external validity
Thirty percent of studies (6/20) did not report the time
from Campylobacter diagnosis to diagnosis of the seque-
lae (Table 2). Fifty-five percent (11/20) of studies did not
report whether or not ReA cases were disease negative
(did not have arthritis) at the time of diagnosis of cam-
pylobacteriosis. Age range and gender distribution werenic sequelae associated with Campylobacter published prior to
Table 1 Population characteristics for studies relating to selected chronic sequelae of Campylobacter published before July 2011
First author, year,
reference number













Pitkanen, 1981 [23] Finland ReA All ages 46 Hospitalized cases Other^ NA 1978-1980 All
Wang, 2008 [24] Taiwan GBS Youth+ 30 Hospitalized cases Other NA 2000-2006 All
Short, 1982 [25] UK ReA NR NR Hospitalized cases Other NA 1979 Summer/Fall
Rowe, 1991 [26] Canada HUS Youth 60 Hospitalized cases Prospective NA 1985 - 1988 All
Petersen, 1996 [27] Denmark ReA All ages 49 Hospitalized cases Prospective NA 1991-1993 All
Saps, 2008 [28] USA & Italy IBS Youth 48 Hospitalized cases Prospective NA 2006 Summer/Fall
Pitkanen, 1983 [29] Finland ReA All ages 47 Hospitalized cases Retrospective NA 1978-1981 All
Spiller, 2000 [30] UK IBS Adults 60 NR Prospective NA NR NR
Spence, 2007 [31] New Zealand IBS NR NR Other Prospective NA Pre-2006 All
Melby, 1990 [32] Norway ReA All ages 48.5 Outbreak in community Prospective Waterborne Pre-1990 Spring/Summer
Bremmel, 1991 [33] Sweden ReA NR 55 Outbreak in community Prospective NR 1981 Fall
Gardner, 2011 [34] USA GBS All ages 1 Outbreak in community Prospective Food - vegetable 2008 Summer/Fall
Eastmond, 1983 [35] Scotland ReA NR NR Outbreak in community Retrospective Food - dairy 1979 Winter
McCarthy, 1999 [36] Sweden GBS NR NR Outbreak in community Retrospective Waterborne 1980,1994, 1995 Fall, Spring, Spring
Locht, 2002 [37] Denmark ReA Adults 56 Surveillance* Other NA 1997-2000 All
Helms, 2006 [38] Denmark GBS, IBD, IBS,
HUS, ReA
All ages 50 Surveillance Retrospective NA 1991 - 1999 All
Kosunen, 1981 [39] Finland ReA, RS NR NR Surveillance NR NA 1978 - 1979 All
Ponka, 1984 [40] Finland ReA All ages NR Surveillance Prospective NA 1978 - 1991 All
Schiellerup, 2008 [41] Denmark ReA Adults 57.1 Surveillance Prospective NA 2002-2003 All
Dunlop, 2003 [42] England IBS Adults nr Surveillance Prospective NA 1999-2002 All
Hannu, 2002 [43] Finland ReA All ages 59 Surveillance Prospective NA 1997-1998 All
Doorduyn, 2008 [44] Netherlands ReA, RS, GBS,
MFS, IBS
NR nr Surveillance Prospective NA 2002-2003, 2005 NR
Moss-Morris 2006, [45] New Zealand IBS Adults 56 Surveillance Prospective NA 2002-2003 All



















Table 1 Population characteristics for studies relating to selected chronic sequelae of Campylobacter published before July 2011 (Continued)
Townes, 2008 [47] USA ReA All ages 50 Surveillance Prospective NA 2002-2004 All
Jess, 2011 [48] Denmark Crohn’s, UC All ages 50 Surveillance Retrospective NA 1992 - 2008 All
Gumpel, 1981 [49] England ReA All ages nr Surveillance Retrospective NA 1978 All
Tam, 2006 [50] UK GBS NR NR Surveillance Retrospective NA 1991 - 2001 All
Scoenberg-Norio,
2010 [51]
Finland ReA All ages 48.3 Surveillance Prospective NA 2002 Summer/Fall
Ternhag, 2008 [52] Sweden GBS, ReA, HUS,
IBS, UC, Crohn’s
All ages 51 Surveillance Retrospective NA 1997-2004 All
McCarthy, 2001 [53] Sweden GBS All ages NR Surveillance Retrospective NA 1987-1995 All
^Other included combinations of both approaches.
*Population surveillance includes laboratory and notifiable disease registries, sporadic cases and other population surveillance. NR = Not Reported.
+Youth were those younger than 18. Adults were ≥ 18 years.
~ReA = reactive arthritis; RS = Reiter’s syndrome; GBS = Guillain Barré syndrome; MFS = Miller-Fisher syndrome; HUS = haemolytic uraemic syndrome; IBS = irritable bowel syndrome; IBD = inflammatory bowel disease;



















Table 2 Outcome variables organized by chronic sequelae for studies relating to Campylobacter published prior to Jul 2011
First author, year,
reference number
Species Sequelae negative prior to diagnosis
with Campylobacter?
Time from Campylobacter












Ternhag, [52] spp. NR 365 NR Physician/medical r ords^ 57425 15 0.03%
Schoenberg-Norio,
[51]
jejuni NR 60 Confirmed+ Physician/medical cords 201 8 3.98%
Townes, [47] NR All were disease negative 42 Confirmed Combination 2384 33 1.38%
Kosunen, [39] jejuni All were disease negative 365 Confirmed Physician/medical cords 342 8 2.34%
Petersen, [27] mix NR NR Confirmed Physician/medical cords 41 0 0%
Short, [25] jejuni NR 240 Confirmed Physician/medical cords 15 0 0%
Hannu, [43] mix All were disease negative 60 Confirmed Physician/medical cords 609 45 7.39%
Hannu, [43] mix All were disease negative 60 Confirmed Combination 609 52 8.54%
Hannu, [43] jejuni All were disease negative 60 Confirmed Specialist 535 37 6.92%
Hannu, [43] coli All were disease negative 60 Confirmed Specialist 61 8 13.11%
Hannu, [43] Undetermined All were disease negative 60 Confirmed Specialist 13 0 0%
Melby, [32] jejuni NR 42 Probable Self-reported diseas status 159 1 0.63%
Pitkanen, [23] jejuni NR NR Confirmed Self-reported diseas status 56 3 5.36%
Locht, [37] mix All were disease negative 28 Confirmed Self-reported diseas status 173 27 15.61%
Schiellerup, [41] NR No – excluded~ 60 Confirmed Self-reported bas on
validated sca
1003 131 13.06%
Hannu, [54] jejuni All were disease negative 90 Probable Specialist 350 9 2.57%
Pitkänen, [29] jejuni All were disease negative NR Confirmed Combination 188 9 4.79%
Helms, [38] NR All were disease negative 365 Confirmed Physician/medical cords 17991 22 0.12%
Ponka, [40] jejuni NR NR Confirmed Self-reported diseas status 283 6 2.12%
Doorduyn, [44] NR NR 1080 Confirmed Self-reported diseas status 434 20 4.61%
Eastmond, [35] jejuni All were disease negative 90 Confirmed Physician/medical cords 88 1 1.14%
Eastmond [35] jejuni All were disease negative 90 Confirmed Physician/medical cords 42 0 0%
Melby, [55] mix NR NR Probable Self-reported diseas status 77 2 2.60%
Gumpel, [49] NR NR NR Confirmed Physician/medical cords 33 8 24.24%
Bremell, [33] NR NR 24 Confirmed Self-reported diseas status 66 1 1.52%
Reiter’s
Kosunen, [39] jejuni All were disease negative Up to 365 Confirmed NR 342 1 0.29%








































Table 2 Outcome variables organized by chronic sequelae for studies relating to Campylobacter published prior to July 2011 (Continued)
IBS
Ternhag, [52] spp NR 365 NR Physician/medical records 57425 15 0.03%
Spence, [31] spp All were disease negative 180 Confirmed Self-reported based on
validated scale
620 49 7.90%
Thornley, [46] spp. All were disease negative 180 Confirmed Self-reported based on
validated scale
188 17 9.04%
Spiller, [30] NR NR 365 Confirmed Self-reported based on
validated scale
31 4 12.90%
Helms, [38] NR All were disease negative 365 Confirmed Physician/medical records 17991 161 0.89%
Doorduyn. [44] NR No – included 1080 Confirmed Self-reported disease status 457 12 2.63%
Saps, [28] NR NR 180 Confirmed Self-reported 6 1 16.67%
Dunlop, [42] jejuni/coli All were disease negative 90 Confirmed Self-reported based on
validated scale
747 103 13.79%
Moss-Morris, [45] NR All were disease negative 90 Confirmed Self-reported based on
validated scale
775 83 10.71%




Helms, [38] NR All were disease negative 365 Culture Physician/Medical records 17991 72 0.40%
UC
Ternhag, [52] spp. NR 365 NR Physician/Medical records 57425 42 0.07%
Jess, [48] NR All were disease negative Up to 16 years Confirmed Physician/Medical records 49420 223 0.45%
Crohn’s
Ternhag, [52] spp. NR 365 NR Physician/Medical records 57425 27, 83 0.05%,
0.17%
Jess, [48] All were disease negative Up to 16 years Confirmed Physician/Medical records 49420 83 0.17%
GBS
Ternhag, [52] spp. NR 90 NR Physician/medical records 57425 13 0.02%
Gardner, [34] jejuni All were disease negative NR Probable Physician/medical records 98 1 1.02%
McCarthy, [36] jejuni No – excluded 180 Probable Physician/medical records 8086 0 0%
Wang, [24] coli NR NR Confirmed Physician/medical records 24 0 0%
Wang, [24] jejuni NR NR Confirmed Physician/medical records 80 0 0%



















Table 2 Outcome variables organized by chronic sequelae for studies relating to Campylobacter published prior to July 2011 (Continued)
McCarthy, [53] NR All were disease negative 180 Confirmed Physician/medical records 29563 9 0.03%
Helms, [38] NR All were disease negative 365 Confirmed Physician/medical records 17991 6 0.03%
Tam, [50] NR All were disease negative 60 NR Physician/medical records 15587 3 0.02%
Doorduyn, [44] NR NR 1080 Confirmed Physician/medical records 457 0 0%
MF
Doorduyn, [44] NR NR 1080 Confirmed Self-reported disease status 457 0 0%
HUS
Ternhag, [52] spp. NR 90 NR Physician/Medical records 57425 2 0%
Helms, [38] NR All were disease negative 90 Confirmed Physician/Medical records 17991 1 0.01%
Rowe, [26] NR All were disease negative NR Confirmed Physician/Medical records 72 0 0%
NR = Not Reported.
^Medical Records/Physician includes those hospitalized for sequelae or diagnosed by a physician.
+ Confirmed for Campylobacter are those confirmed by culture, DNA based tests or serology. Probable cases were based on case definition given in study.




















Figure 2 Distribution of estimates of the proportion of Campylobacter cases that develop reactive arthritis from studies published
prior to July 2011.
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spectively. Data source was reported in all studies how-
ever in one study it was not possible to determine study
directionality. The method for Campylobacter diagnosis
was reported in all studies but one, and the methods of
sequelae diagnosis (physician vs. self-reported) were re-
ported in all studies. However, the specific diagnostic
criteria for sequelae diagnosis were not provided for 40%
(8/20) of studies.Meta-analysis/meta-regression
A total of 25 outcome measures were included. The over-
all summary estimate of the proportion of cases of
Campylobacter that developed ReA was 2.86% (95% CI
1.4% - 5.61%). Heterogeneity was high at 97.7% (Figure 3).
Due to high heterogeneity, exploration of factors influen-
cing the outcome measure was performed using meta-
regression.
Variables found to have a significant contribution to
the heterogeneity in univariable meta-regression were
group size (p = 0.015), follow-up time (p = 0.005) and
Campylobacter species (p = 0.014). Due to the limited
number of studies providing information for all of these
factors (n = 12) and evidence of non-independence within
studies (all of the medium size outcome measures were
from the same study), multivariable analysis incorporating
all three categories was not possible. Therefore all three of
these factors were explored individually with subgroup
meta-analysis.Based on follow-up time, the proportion of cases of
Campylobacter that developed ReA ranged from 0.44%
(95% CI 0.04% - 4.77%, I2 = 98.9%) in studies following
patients for a year or more to 5.92% (95% CI 3.51% -
9.81%, I2 = 94.2%) in studies with a follow up of less than
90 days (Table 3). A lower proportion of cases of Cam-
pylobacter jejuni developed ReA (3.29%; 95% CI 2.18% -
4.93%, I2 = 58.8%) versus those that were a mix of or
unidentified species (8.27%; 95% CI 5.41% - 12.46%,
I2 = 70.4%) (Table 3). Group size demonstrated a large
range, in groups with case numbers of 10 000 or more the
summary estimates for ReA was 0.06% (95% CI 0.01% -
0.26%, I2 = 95.3%) of Campylobacter cases developing ReA
versus 4.55% (95% CI 1.99% - 10.07%, I2 = 66.7%) in those
studies with under 100 cases (Table 3).Reiter’s syndrome
A closely related subtype of ReA is Reiter’s syndrome (RS)
which is characterized by arthritis in combination with
conjunctivitis, and urethritis [17]. Two studies reporting
on ReA also reported outcome measures specific to the
related sequelae of RS. The proportion of culture con-
firmed cases of Campylobacter developing RS were 0%
and 0.29%.Irritable bowel syndrome
Study descriptions
Nine studies provided information on Campylobacter
and irritable bowel syndrome (IBS) (Table 1). The nine
Figure 3 Forest plot of the proportion of cases of reactive arthritis from studies published before July 2011.
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the studies presenting both US and Italian data. The ma-
jority (77%, 7/9), were based on surveillance data and
were prospective (89%, 8/9). Follow-up times ranged
from three months (90 days) to three years (1080 days).Outcome measures
There were ten different outcome measures, as one
study [45] included more than one outcome measure.
The proportion of confirmed cases of Campylobacter
that developed IBS ranged from 0.03% to 0.89% in those
studies reporting IBS diagnosis from medical records;
7.89% to 13.79% for those diagnosed using a self-reportaccording to a validated scale (Rome I and Rome I
modified [56] criteria or Rome II [57] criteria, Gastro-
intestinal Symptom Rating Score [58]) and 2.63% to
16.63% in those that were self-reported cases of IBS
(Table 2).Assessment of internal and external validity
Data on age range and gender distribution were missing
from 22% (2/9) and 44% (4/9) of studies respectively.
Study directionality could be determined in all studies
however the source of data was missing from one
(Table 2). The time between Campylobacter diagnosis
and diagnosis of IBS was reported in all studies.
Table 3 Results of subgroup meta- analyses for Campylobacter and reactive arthritis from studies published prior to
July 2011
Variable Summary estimate Lower 95% CI Upper 95% CI I2 Number of outcome
measures
Overall Estimate 2.86% 1.4% 5.61% 97.7% 25
Follow Up Time
Over a year 0.44% 0.04% 4.77% 98.9% 4
> 3 months to < year 3.42% 14.84% 12.92% 91.0% 4
< 3 months 5.92% 3.51% 9.81% 94.2% 11
Species
Jejuni 3.29% 2.18% 4.93% 58.8% 11
Mix/undetermined* 8.27% 5.41% 12.46% 70.4% 6
Group Size
Extra small 4.55% 1.99% 10.07% 66.7% 10
Small 3.73% 1.99% 6.33% 87.1% 8
Medium ^ ^ ^ ^ 3
Large 4.41% 0.45% 32.02% 99.3% 2
Extra large 0.06% 0.01% 0.26% 95.3% 2
*Included combinations of jejuni, coli, spp and undetermined species.
^Not calculated, no variation between variables of interest as all outcome measures were from the same study.
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missing from a single study. Six studies reported on
whether or not cases were disease negative for IBS prior
to the study and a single study included those with a
history of IBS in their outcome measure. The method of
diagnosing IBS was reported in all studies but three
studies did not provide the specific criteria for their
diagnosis of IBS.
Meta-analysis/meta-regression
A total of 10 outcome measures were included in the
analysis. The estimate for the proportion of cases of
Campylobacter that developed IBS was 4.01% (95% CI
1.41% - 10.88%, I2 = 99.2%) (Figure 4). The high hetero-
geneity supported investigation of influencing variables
with meta-regression. In univariable analyses, group
size (p = 0.04), study directionality (p = 0.001) and the
method of diagnosing IBS (p = 0.05) significantly con-
tributed to heterogeneity. The limited number of studies
and evidence that variables were associated (all large
studies were retrospective, physician diagnosed) pre-
vented multivariable meta-regression. Subgroup meta-
analysis was therefore performed for all significant
factors.
Subgroup meta-analysis demonstrated that the number
of cases of Campylobacter that developed IBS in prospect-
ive studies was 8.64% (95% CI 6.36% - 11.66%, I2 = 83.7%)
versus 0.15% (95% CI 0.0048% - 4.75%, I2 = 99.4%) in
retrospective studies (Table 4). The proportion of cases ofCampylobacter that developed IBS varied between method
of sequelae diagnosis with self-reported cases (using
validated scale) estimated at 9.94% (95% CI 7.90% -
12.44%, I2 = 73.6%) versus 5.27% (95% CI 0.84% - 26.84%,
I2 = 68.0%) in self-reported cases and 0.15% (0.0048% -
4.75%, I2 = 99.4%) in cases of IBS identified from medical
records. For studies with fewer than 100 cases of Cam-
pylobacter, 13.56% (95% CI 5.76% - 28.74%, I2 = 0%) of
cases developed IBS versus 0.15% (95% CI 0.0048% -
4.75%, I2 = 99.4) of cases in studies with greater than
10000 participants.Inflammatory bowel disease including crohn’s disease
and ulcerative colitis
Inflammatory bowel disease encompasses two separate
diseases, Crohn’s disease and ulcerative colitis (UC)
which have closely related pathologies but are consid-
ered independent entities [57]. A single study reported
the proportion of Campylobacter cases that developed
IBD and two studies evaluated Crohn’s and UC. The
proportion of culture confirmed Campylobacter cases
developing IBD was 0.4%. For Crohn’s and UC, both
studies were large retrospective surveillance studies.
For confirmed cases of Campylobacter, 0.16% devel-
oped Crohn’s and 0.45% developed UC versus 0.047%
developed Crohn’s and 0.07% developed UC in the study
where the method of Campylobacter diagnosis was not
reported.
Figure 4 Forest plot of the proportion of cases of Campylobacter that develop irritable bowel syndrome from studies published before
July 2011.
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Study descriptions
Eight studies from six countries provided estimates for the
number of cases of Campylobacter that developed GBS
(Table 1). The majority (5/8) were based on surveillance
data and with the data collected retrospectively (6/8). Fol-
low up times ranged from two months to three years.Outcome measures
There were ten different outcome measures (Table 2) as
one study [24] reported multiple outcome measures. The
proportion of confirmed cases of Campylobacter that de-
veloped GBS ranged from 0% to 2.08% with case numbersvarying from 24 to 29563 cases of Campylobacter (n = 4
studies). For probable cases of Campylobacter, the pro-
portion developing GBS ranged from 0.01% to 1.02%
with Campylobacter case numbers ranging from 98 to
8086 (n = 2 studies) (Table 2).Assessment of internal and external validity
Data on age range and gender distribution of Campylo-
bacter cases were missing from 38% (3/8) and 50% (4/8)
of studies, respectively (Table 2). The source of data and
study directionality were reported in all studies. Two
studies did not report the method of Campylobacter
diagnosis. An additional two studies did not report follow-
Table 4 Results of subgroup meta- analyses for Campylobacter and irritable bowel syndrome from studies published
prior to July 2011
Variable Summary Estimate Lower 95% CI Upper 95% CI I2 Number of outcome
measures
Overall Estimate 4.01% 1.41% 10.88% 99.2% 10
Study Directionality
Prospective 8.64% 6.36% 11.66% 83.7% 8
Retrospective 0.15% 0.0048% 4.75% 99.4 2
Method of Assessing Sequelae
Self-reported 5.27% 0.84% 26.84% 68.0% 2
Self-reported based on validated scale* 9.94% 7.90% 12.44% 73.6% 6
Based on medical records 0.15% 0.0048% 4.75% 99.4% 2
Group Size
Small 13.56% 5.76% 28.74% 0.0% 2
Medium 4.96% 1.43% 15.79% 91.2% 2
Large 9.92% 7.52% 12.98% 83.6% 4
Extra large 0.15% 0.0048% 4.75% 99.4 2
*Questionnaires using self-reported responses to Rome I/Rome II criteria.
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disease negative prior to the onset of campylobacteriosis.
All studies reported the method of diagnosis for the se-
quelae but the majority (62.5%, 5/8) did not report the
specific diagnostic criteria used for their diagnosis of GBS.
Meta-analysis/meta-regression
There were ten outcome measures between the 8 stud-
ies. Five of those reported no cases of GBS. The propor-
tion of cases of Campylobacter that developed GBS was
estimated at 0.07% (95% CI. 0.03% - 0.15%, I2 = 72.7%)
(Figure 5). Both group size (p = 0.001) and data source
(p = 0.04) significantly contributed to heterogeneity. Multi-
variable meta-regression and subgroup analysis was not
conducted given the limited data.
Miller fisher syndrome
Miller-Fisher syndrome is a subtype of GBS [59]. One
study reporting on GBS also reported outcome measures
specific to MFS. Of the 457 cases of Campylobacter,
none developed MFS (Table 2).
Haemolytic uraemic syndrome
Three studies provided estimates for the proportion of
cases of Campylobacter that developed HUS (Table 1). In a
study of children hospitalized for Campylobacter infection,
no cases of HUS were reported. The two surveillance based
studies reported estimates of 0.005% and 0.003% (Table 2).
Discussion
This study used a systematic literature search and meta-
analysis to provide estimates for the number of cases of
Campylobacter that develop the chronic sequelae ofreactive arthritis, irritable bowel syndrome or Guillain
Barré syndrome. Considering the high incidence of
Campylobacter and the potential severity of its associated
chronic sequelae, there was limited research available. Not
enough data were available to develop summary estimates
for inflammatory bowel disease and haemolytic uraemic
syndrome. A strength of systematic reviews is that they at-
tempt to systematically identify all information on a topic
and present the methodology and results in a transparent
and reproducible manner [11]. Even with the broad ter-
minology used for the search terms and large number po-
tentially relevant citations identified in this review, only 31
studies for chronic sequelae associated with Campylobac-
ter infection were identified internationally. Within these
31 studies, the occurrence of chronic sequelae following
infection varied greatly. For those sequela where suffi-
cient publications were found to develop estimates using
meta-analysis, the heterogeneity associated with these es-
timates was very high [22] indicating that the summary
estimates must be interpreted with caution and within
the context of those variables that were found through
meta-regression to significantly influence heterogeneity.
Multiple factors were found to significantly affect het-
erogeneity depending on the sequela being considered.
Group size was the only factor that was consistently in-
fluential between sequela estimates, with smaller studies
reporting a higher proportion of sequela. This effect
could be attributed in part to differences in how sequela
cases are captured between smaller outbreak studies and
larger surveillance or registry based studies. Large popu-
lation based studies may only identify the severe cases of
sequela, while individuals in smaller studies may have
been followed more closely increasing the likelihood that
Figure 5 Forest plot of the proportion of cases of Campylobacter that develop Guillain Barre syndrome from studies published before
July 2011.
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relevant to sequelae such as ReA or IBS in which sever-
ity would be influenced by personal perception [60] ver-
sus Guillain Barré syndrome which is medically severe
and is less likely to remain unidentified [16]. The effect
of physician diagnosis versus self-report was seen in the
meta-regression for IBS as studies using medical records
had a much lower proportion of IBS cases than self-
reported cases.
Follow-up time was significant for ReA but not IBS
and GBS. For reactive arthritis individual variation in
disease symptoms and recovery has been reported along
with a wide range of proposed timelines for disease de-
velopment [17,61]. Because of this, understanding of dis-
ease progression (from onset to recovery) is unclear and
no standard guidelines for disease duration have been
accepted within the medical field; which could explain
some of the variation in follow-up times used between
studies. The association between follow-up time and the
development of reactive arthritis suggests a peak withinthe first 90 days after infection. However, the association
observed could be explained by differences in how stud-
ies assess a case of ReA and whether they were consider-
ing incident or prevalent cases at the time of follow-up.
For example, were the cases captured after a one year
follow-up prevalent cases which developed ReA within
the first 90 days and did not recover or were they new
incidence cases that took longer to develop and which
were not present within those first 90 days. Given the
minimal details provided on the specifics used to assess
ReA in many of these studies, it is not possible to inter-
pret the effect of incident vs. prevalent cases. Further in-
vestigation into disease duration is recommended as this
could have significant effects on disease burden estimates.
A large number of cases of ReA within the first few
months after infection that recover without complication
could require vastly different health care resources then
long term chronic cases of ReA that require ongoing med-
ical attention. Additionally, some sequelae cases could
have developed these chronic sequelae regardless of
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velop without previous infection.
The lack of association between follow-up time and
IBS and GBS diagnosis is difficult to interpret given the
limited available data. For GBS half of the studies did
not report follow up time, for IBS the lack of association
could indicate more long term duration for the disease.
However, the limited data available prevented full ex-
ploration of this theory. For all sequela, the effect of fol-
low up time would be greatly influenced by when the
follow-up questions were administered and how they
were worded. For example, changing the wording from
“are you currently suffering from any of the following
symptoms?” to “have you ever suffered from any of the
following symptoms since diagnosis with Campylobac-
ter?” could yield different results. Due to the limited in-
formation reported in most publications, assessing what
effect this would have on the results was not possible.
For the other factors that significantly affected hetero-
geneity, the limited data available also needs to be con-
sidered while interpreting the results. For directionality,
which was significant for IBS, the number of studies pre-
vents interpretation as the retrospective studies were
also large surveillance studies with very low outcome es-
timates. Additionally, the effect of “method of diagnosis
for the sequelae” should be interpreted with caution as
the limited information for those studies identified as
“cases taken from medical records” prevents distinguish-
ing if the same scales were used in those studies classified
as “self-reported based on validated scale”. In addition, in-
terpretation can differ between physicians and lead to po-
tentially biased results, for example ICD classification
allows for subjective interpretation of symptoms [62]. Fi-
nally, the effect of Campylobacter species was significant
for ReA however its true influence is impossible to distin-
guish as Campylobacter jejuni was included in the studies
classified as mixed and therefore specific comparisons be-
tween the effects of species were not possible. Addition-
ally, truly exploring the effect of species is not possible
based on the limited amount of information published on
Campylobacter species other than C. jejuni. Consequently,
despite exploring factors affecting heterogeneity with
meta-regression, the majority of this variation remains un-
explained as heterogeneity remained high even with sub-
group meta-analysis.
The remaining high heterogeneity suggests that poten-
tially influential factors were not captured in this review.
This meta-regression focused on study level variables,
such as study design, case definitions etc. However host
related factors such race, severity of acute illness, the
age of Campylobacter cases and sequelae cases, medical
history or immune status and pathogen related factors
such as virulence and dose have been identified as po-
tential influential factors in sequelae development[13,14,59]. As a result of the many factors that could po-
tentially affect the likelihood of sequelae development,
predicting the proportion of cases of Campylobacter that
develop chronic sequelae is challenging.
A first step in addressing this challenge would be to
increase the accuracy of future estimates through add-
itional high quality data. The effect of lack of reporting
of non-results could be influential. In many cases publi-
cations reported on the results for a specific sequelae
and it was not possible to determine if other sequelae
were absent, were not evaluated, or were evaluated but
not reported. Additionally, as under-reporting and under-
diagnosis of foodborne diseases is well-established [3],
there is the potential that cases of sequelae are not being
linked to previous infection as these infections have not
been identified. For sequelae that can take weeks or
months to develop, a previous GI experience may never
be linked and therefore not captured in the literature.
The limited information available not only affected our
ability to explore heterogeneity in the data, it also raises
questions surrounding our current understanding of
these diseases. For instance, the link between GBS and
campylobacteriosis is widely accepted [4,5,15,16,18]. The
basis for this assumption may be related to the numer-
ous case–control studies published [16] that were ex-
cluded from this review because they considered GBS
cases with evidence of previous Campylobacter expos-
ure. Although this study design indicates a relationship,
the lack of temporal relationship and the limited re-
search identified by this systematic review indicate that
perhaps the magnitude of the relationship between GBS
and Campylobacter is not clear. As GBS infection has high
mortality, at two to three percent, and 15 to 20 percent of
cases develop severe permanent neurological defects [16]
further investigation into the role Campylobacter infection
plays in GBS development is recommended.
In addition, reporting of irritable bowel syndrome as a
sequelae linked to Campylobacter in burden of disease/
cost estimates is inconsistent [9,10,63-65]. The results of
this systematic review support the inclusion of IBS in
BOD estimates for Campylobacter. The lack of informa-
tion available on IBD raises an interesting issue as it is
often reported as linked to Campylobacter infection
within BOD estimates. Our search located only five
studies with information related to IBD. Both IBD and
IBS are associated with similar symptoms, such as ab-
dominal pain, bloating and diarrhea, with both occurring
simultaneously in some cases [60]. This overlap intro-
duces the possibility for misdiagnosis and under diagno-
sis of these sequelae. Discrepancies between terminology
use, case definitions and diagnostic criteria and the lack
of information available on the association between IBD
and Campylobacter infection indicate the need for fur-
ther research. Further research into the mechanisms of
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provide more clarity surrounding disease development
and links to infection with foodborne pathogens such as
Campylobacter.
Terminology issues may be a concern with the other
sequelae, such as with ReA and Reiter’s syndrome, as
terminologies are used interchangeably and there is no
standard classification or diagnostic criteria that are uni-
versally accepted by the medical community [66]. As
many publications did not provide the details of their
case definitions for the sequelae and case definitions var-
ied between studies determining the influence this might
have on outcome measures was hard to estimate. With-
out distinct criteria reported within studies, it can be dif-
ficult to distinguish which syndromes are actually being
assessed and whether they are the same between studies,
thereby increasing the complexity involved with identify-
ing relevant studies, contributing to inaccurate estimates
and potentially to heterogeneity.
Although the results of this meta-analysis can be used
as a starting point to inform burden of disease estimates,
the results should be interpreted in the context of the
study variables. Inaccessible articles and language re-
strictions may have prevented the review from having a
fully international perspective. Limiting the study results
to English language articles prevented the exploration of
the effect of country in detail. Additionally, understand-
ing the burden chronic sequelae has in developing coun-
tries is an important area for future research. Because
multiple outcomes were taken from some studies, the
assumption of independence of estimates within studies
was not met. For the sequelae that underwent meta-
analysis, this could lead to deflated estimates and narrow
confidence intervals for the proportion of cases of Cam-
pylobacter that develop a sequela. Due to the limited
amount of data, adjusting for non-independence by aver-
aging the results [66] would have resulted in too few
studies to explore with meta-regression. Additionally,
the categorization of group size and follow-up time were
determined post hoc based on the data. Inconsistencies
in the case definitions used for probable cases of Cam-
pylobacter between studies could also affect the accuracy
of the proportions reported. For example, studies using
a broader definition for a Campylobacter case would re-
sult in higher case numbers and a lower proportion for
the sequela estimate versus a study with a more strin-
gent definition for a Campylobacter case. Many variables
varied together consistently across subgroups (for ex-
ample extra-large populations were often prospective
surveillance studies). Combined with these associations,
the high heterogeneity and limited number of studies
prevented a full meta-regression and sub group meta-
analysis therefore all results must be interpreted with
caution.Despite these limitations, the potential burden of long term
health complications attributed to these diseases is important
considering the high worldwide incidence of campylo-
bacteriosis. Even using the low estimates for the proportion
of cases that develop ReA, IBS or GBS, there is the potential
for tens of thousands of sequelae cases yearly in North
America alone. Considering the long term nature and poten-
tial severity of these associated health complications, this
could contribute to a significant decrease in quality of life
and a significant burden on health care systems worldwide.
Conclusions
The proportion of Campylobacter cases developing chronic
sequelae varied greatly depending on a variety of factors,
not all of which were identified in this review. Estimates for
the proportion of cases of reactive arthritis, irritable bowel
syndrome and Guillain Barré syndrome were, 2.86% (95%
CI 1.4% - 5.61%), 4.01% (95% CI 1.41% - 10.88%) and 0.07%
(95% CI. 0.03% - 0.15) respectively. These results should be
interpreted with caution due to the high heterogeneity
and limited data which prevented detailed exploration of
sources of heterogeneity. Although these are the best esti-
mates currently available based on all international sources,
in order for more accurate estimates to be developed ex-
ploration of non-English language studies is recommended
and consistent diagnostic approaches and case definitions
need to be implemented and reported in future research.
Additional file
Additional file 1: PRISMA 2009 Flow Diagram Campylobacter SLR.
Abbreviations
AGI: Acute gastrointestinal illness; REA: Reactive arthritis; RS: Reiter’s
syndrome; HUS: Haemolytic uraemic syndrome; IBS: Irritable bowel
syndrome; IBD: Inflammatory bowel disease; GBS: Guillain Barré syndrome;
MFS: Miller Fisher syndrome; ONBOIDS: Ontario Burden of Infectious Disease
Study; UC: Ulcerative colitis; Crohn’s: Crohn’s disease.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
KT and AF made contributions to conception and design. JK made
substantial contributions to conception and design, acquisition of data,
analysis and interpretation of data; JK, JS, KT were involved in drafting the
manuscript and revising it critically for important intellectual content. All
have given final approval of the version to be published and agree to be
accountable for all aspects of the work in ensuring that questions related to
the accuracy or integrity of any part of the work are appropriately
investigated. All authors read and approved the final mauscript.
Acknowledgements
The authors thank Mai Pham, Ashley Whiteman, Dianna Wolfe, Tyler O’Neil,
and Theresa Procter for technical assistance with this study. Funding for this
research was received from a Canadian Institutes of Health Research (CIHR)
Institute of Population and Public Health/Public Health Agency of Canada
Applied Public Health Research Chair (awarded to J.M. Sargeant). In addition,
financial and in-kind support was provided by the Public Health Agency of
Canada.
Keithlin et al. BMC Public Health 2014, 14:1203 Page 18 of 19
http://www.biomedcentral.com/1471-2458/14/1203Author details
1Centre for Public Health and Zoonoses, University of Guelph, Guelph,
Ontario, Canada. 2Department of Population Medicine, Ontario Veterinary
College, Guelph, Ontario, Canada. 3Centre for Food-borne, Environmental
and Zoonotic Infectious Diseases, Public Health Agency of Canada, Guelph,
Ontario, Canada. 4Laboratory for Foodborne Zoonoses, Public Health Agency
of Canada, Guelph, Ontario, Canada.
Received: 4 April 2014 Accepted: 30 September 2014
Published: 22 November 2014
References
1. Scallan E, Hoekstra RM, Angulo FG, Tauxe RV, Widdowson MA, Roy SL, Jones
JL, Griffin PM: Foodborne illness acquired in the United States - major
pathogens. Emerg Infect Dis 2011, 17:7.
2. Government of Canada: Canadian Notifiable Disease Surveillance System
National Report (2005–2008). Canada: Public Health Agency of Canada; 2012.
3. Thomas MK, Majowicz SE, Sockett PN, Fazil A, Pollari F, Doré K, Flint JA, Edge
VL: Estimated numbers of community cases of illness due to Salmonella,
Campylobacter and verotoxigenic Escherichia coli: Pathogen-specific
community rates. Can J Infect Dis Med Microbiol 2006, 17:229–234.
4. Smith JL: Campylobacter jejuni infection during pregnancy: Long-term
consequences of associated bacteremia, Guillain-Barré syndrome, and
reactive arthritis. J Food Prot 2002, 65:696–708.
5. Peterson MC: Clinical aspects of Campylobacter jejuni infections in adults.
West J Med 1994, 161:148–152.
6. Abley MJ, Wittum TE, Funk JA, Gebreyes WA: Antimicrobial susceptibility,
pulsed-field gel electrophoresis, and multi-locus sequence typing of
Campylobacter coli in swine before, during, and after the slaughter
process. Foodborne Pathog Dis 2012, 9:506–512.
7. Hermans D, Pasmans F, Messens W, Martel A, Van Immerseel F, Rasschaert G,
Heyndrickx M, Van Deun K, Haesebrouck F: Poultry as a host for the zoonotic
pathogen Campylobacter jejuni. Vector Borne Zoonotic Dis 2012, 12:89–98.
8. Domingues AR, Pires SM, Halasa T, Hald T: Source attribution of human
campylobacteriosis using a meta-analysis of case–control studies of
sporadic infections. Epidemiol Infect 2012, 140:970–981.
9. Kwong JC, Crowcroft NS, Campitelli MA, Ratnasingham S, Daneman N,
Deeks SL, Manuel DG: Ontario burden of infectious disease study (ONBOIDS):
An OAHPP/ICES report. Toronto: Ontario Agency for Health Protection and
Promotion, Institute for Clinical Evaluative Sciences; 2010.
10. Havelaar AH, Haagsma JA, Mangen MJ, Kemmeren JM, Verhoef LP, Vijgen
SM, Wilson M, Friesema IH, Kortbeek LM, van Duynhoven YT, van Pelt W:
Disease burden of foodborne pathogens in the Netherlands, 2009. Int J
Food Microbiol 2012, 156:231–238.
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke
M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting
systematic reviews and meta-analysis of studies that evaluate health
care interventions. Br Med J 2009, 6:1–28.
12. Higgins JPT, Green S: Cochrane handbook for systematic reviews of
interventions version 5.1.0. Cochrane Collaboration 2011, 5:1.
13. Thabane M, Kottachchi DT, Marshall JK: Systematic review and meta-
analysis: The incidence and prognosis of post-infectious irritable bowel
syndrome. Aliment Pharmacol Ther 2007, 26:535–544.
14. Karlinger K, Gyorke T, Mako E, Mester A, Tarján Z: The epidemiology and the
pathogenesis of inflammatory bowel disease. Eur J Radiol 2000, 35:154–167.
15. Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y: Guillain-Barré
syndrome–a classical autoimmune disease triggered by infection or
vaccination. Clin Rev Allergy Immunol 2012, 42:121–130.
16. Nachamkin I, Allos BM, Ho T: Campylobacter species and Guillain-Barré
syndrome. Clin Microbiol Rev 1998, 11:555–567.
17. Pope JE, Krizova A, Garg AX, Thiessen-Philbrook H, Ouimet JM: Campylobacter
reactive arthritis: A systematic review. Semin Arthritis Rheum 2007, 37:48–55.
18. Poropatich KO, Walker CL, Black RE: Quantifying the association between
Campylobacter infection and Guillain-Barré syndrome: A systematic
review. J Health Popul Nutr 2010, 28:545–552.
19. Riddle MS, Gutierrez RL, Verdu EF, Porter CK: The chronic gastrointestinal
consequences associated with Campylobacter. Curr Gastroenterol Rep 2012,
14:395–405.
20. Sanchez J, Dohoo IR, Christensen J, Rajic A: Factors influencing the
prevalence of Salmonella spp. in swine farms: A meta-analysis approach.
Prev Vet Med 2007, 81:148–177.21. Egger M, Smith D, Altmand DG: Systematic reviews in health care: Meta-
analysis in context. 2nd edition. London: BMJ Publishing Group; 2001.
22. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis.
Stat Med 2002, 21:1539–1558.
23. Pitkanen T, Pettersson T, Ponka A, Kosunen TU: Clinical and serological
studies in patients with Campylobacter fetus/ssp/jejuni infection: clinical
findings. Infection 1981, 9:274–278.
24. Wang SC, Chang LY, Hsueh PR, Lu CY, Lee PI, Shao PL, Hsieh YC, Yen FP,
Lee CY, Huang LM: Campylobacter enteritis in children in northern
Taiwan–a 7-year experience. J Microbiol Immunol Infect 2008, 41:408–413.
25. Short CD, Klouda PT, Smith L: Campylobacter jejuni/enteritis and reactive
arthritis. Ann Rheum Dis 1982, 41:287–288.
26. Rowe PC, Walop W, Lior H, Mackenzie AM: Haemolytic anaemia after
childhood Escherichia coli O 157.H7 infection: Are females at increased
risk? Epidemiol Infect 1991, 106:523–530.
27. Petersen AM, Nielsen SV, Meyer D, Ganer P, Ladefoged K: Bacterial
gastroenteritis among hospitalized patients in a Danish county, 1991–93.
Scand J Gastroenterol 1996, 31:906–911.
28. Saps M, Pensabene L, Di Martino L, Staiano A, Wechsler J, Zheng X,
Di Lorenzo C: Post-infectious functional gastrointestinal disorders in
children. J Pediatr 2008, 152:812–816.
29. Pitkänen T, Pönkä A, Peterson T, Kosunen TU: Campylobacter enteritis in
188 hospitalized patients. Arch Intern Med 1983, 143:215–219.
30. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR:
Increased rectal mucosal enteroendocrine cells, T lymphocytes, and
increased gut permeability following acute Campylobacter enteritis and
in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804–811.
31. Spence MJ, Moss-Morris R: The cognitive behavioral model of irritable
bowel syndrome: A prospective investigation of patients with
gastroenteritis. Gut 2007, 56:1066–1071.
32. Melby K, Dahl OP, Crisp L, Penner JL: Clinical and serological
manifestations in patients during a waterborne epidemic due to
Campylobacter jejuni. J Infect 1990, 21:309–316.
33. Bremell T, Bjelle A, Svedhem A: Rheumatic symptoms following an outbreak
of Campylobacter enteritis: A five year follow up. Ann Rheum Dis 1991,
50:934–938.
34. Gardner TJ, Fitzgerald C, Xavier C, Klein R, Pruckler J, Stroika S, McLaughlin
JB: Outbreak of campylobacteriosis associated with consumption of raw
peas. Clin Infect Dis 2011, 53:26–32.
35. Eastmond CJ, Rennie JA, Reid TM: An outbreak of Campylobacter enteritis–a
rheumatological follow up survey. J Rheumatol 1983, 10:107–108.
36. McCarthy N, Andersson Y, Jormanainen V, Gustavsson O, Giesecke J: The
risk of Guillain-Barré syndrome following infection with Campylobacter
jejuni. Epidemiol Infect 1999, 122:15–17.
37. Locht H, Krogfelt KA: Comparison of rheumatological and gastrointestinal
symptoms after infection with Campylobacter jejuni/coli and
enterotoxigenic Escherichia coli. Ann Rheum Dis 2002, 61:448–452.
38. Helms M, Simonsen J, Molbak K: Foodborne bacterial infection and
hospitalization: A registry-based study. Clin Infect Dis 2006, 42:498–506.
39. Kosunen TU, Ponka A, Kauranen O, Martio J, Pitkänen T, Hortling L,
Aittoniemi S, Penttilä O, Koskimies S: Arthritis associated with
Campylobacter jejuni/enteritis. Scand J Rheumatol 1981, 10:77–80.
40. Ponka A, Pitkanen T, Sarna S, Kosunen TU: Infection due to Campylobacter
jejuni: A report of 524 outpatients. Infection 1984, 12:175–178.
41. Schiellerup P, Krogfelt KA, Locht H: A comparison of self-reported joint
symptoms following infection with different enteric pathogens:
Effect of HLA-B27. J Rheumatol 2008, 35:480–487.
42. Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of
enterochromaffin cell hyperplasia, anxiety, and depression in post
infectious IBS. Gastroenterology 2003, 125:1651–1659.
43. Hannu T, Mattila L, Rautelin H, Pelkonen P, Lahdenne P, Siitonen A, Leirisalo-Repo M:
Campylobacter-triggered reactive arthritis: A population-based study.
Rheumatology 2002, 41:312–318.
44. Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT,
Hoebee B, Janssen R: Novel insight in the association between salmonellosis
or campylobacteriosis and chronic illness, and the role of host genetics in
susceptibility to these diseases. Epidemiol Infect 2008, 136:1225–1234.
45. Moss-Morris R, Spence M: To “lump” or to “split” the functional somatic
syndromes: Can infectious and emotional risk factors differentiate
between the onset of chronic fatigue syndrome and irritable bowel
syndrome? Psychosom Med 2006, 68:463–469.
Keithlin et al. BMC Public Health 2014, 14:1203 Page 19 of 19
http://www.biomedcentral.com/1471-2458/14/120346. Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC: Relationship
of Campylobacter toxigenicity in vitro to the development of post
infectious irritable bowel syndrome. J Infect Dis 2001, 184:606–609.
47. Townes JM, Deodhar AA, Laine ES, Smith K, Krug HE, Barkhuizen A,
Thompson ME, Cieslak PR, Sobel J: Reactive arthritis following culture-
confirmed infections with bacterial enteric pathogens in Minnesota and
Oregon: A population-based study. Ann Rheum Dis 2008, 67:1689–1696.
48. Jess T, Simonsen J, Nielsen NM, Jørgensen KT, Bager P, Ethelberg S, Frisch
M: Enteric Salmonella or Campylobacter infections and the risk of
inflammatory bowel disease. Gut 2011, 60:318–324.
49. Gumpel JM, Martin C, Sanderson PJ: Reactive arthritis associated with
Campylobacter enteritis. Ann Rheum Dis 1981, 40:64–65.
50. Tam CC, Rodrigues LC, Petersen I, Islam A, Hayward A, O'Brien SJ: Incidence of
Guillain-Barré syndrome among patients with Campylobacter infection: A
general practice research database study. J Infect Dis 2006, 194:95–97.
51. Schoenberg-Norio D, Mattila L, Lauhio A, Katila ML, Kaukoranta SS, Koskela
M, Pajarre S, Uksila J, Eerola E, Sarna S, Rautelin H: Patient-reported
complications associated with Campylobacter jejuni infection. Epidemiol
Infect 2010, 138:1004–1011.
52. Ternhag A, Torner A, Svensson A, Ekdahl K, Giesecke J: Short- and long-
term effects of bacterial gastrointestinal infections. Emerg Infect Dis 2008,
14:143–148.
53. McCarthy N, Giesecke J: Incidence of Guillain-Barré syndrome following
infection with Campylobacter jejuni. Am J Epidemiol 2001, 153:610–614.
54. Hannu T, Kauppi M, Tuomala M, Laaksonen I, Klemets P, Kuusi M: Reactive
arthritis following an outbreak of Campylobacter jejuni infection.
J Rheumatol 2004, 31:528–530.
55. Melby KK, Svendby JG, Eggebo T, Holmen LA, Andersen BM, Lind L, Sjøgren
E, Kaijser B: Outbreak of Campylobacter infection in a subarctic
community. Eur J Clin Microbiol Infect Dis 2000, 19:542–544.
56. Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G: Functional
bowel disease and functional abdominal pain. Gastroenterol Int 1992, 5:75.
57. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ,
Muller-Lissner SA: Functional bowel disorders and functional abdominal
pain. Gut 1999, 45:43.
58. Svedlund J, Sjodin I, Dotevall G: GSRS–a clinical rating scale for
gastrointestinal symptoms in patients with irritable bowel syndrome and
peptic ulcer disease. Dig Dis Sci 1988, 33:129–134.
59. Hughes RA, Hadden RD, Gregson NA, Smith KJ: Pathogenesis of Guillain-
Barré syndrome. J Neuroimmunol 1999, 100:74–97.
60. Ohman L, Simren M: Pathogenesis of IBS: Role of inflammation, immunity
and neuroimmune interactions. Gastroenterol Hepatol 2010, 7:163–173.
61. Townes JM: Reactive arthritis after enteric infections in the United States:
The problem of definition. Clin Infect Dis 2010, 50:247–254.
62. World Health Organization: International classification of Diseases; 2012.
63. Withington SG, Chambers ST: The cost of campylobacteriosis in New
Zealand in 1995. N Z Med J 1997, 110:222–224.
64. Mangen MJ, Havelaar AH, Bernsen R, Van Koningsveld R, De Wit GA: The costs
of human Campylobacter infections and sequelae in the Netherlands: A
DALY and cost-of-illness approach. Food Econ 2005, 2:35–51.
65. Ruzante JM, Majowicz SE, Fazil A, Davidson VJ: Hospitalization and deaths
for select enteric illnesses and associated sequelae in Canada, 2001–
2004. Epidemiol Infect 2011, 139:937–945.
66. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR: Introduction to meta-
analysis. John Wiley and Sons, Ltd: United Kingdom; 2009.
doi:10.1186/1471-2458-14-1203
Cite this article as: Keithlin et al.: Systematic review and meta-analysis of
the proportion of Campylobacter cases that develop chronic sequelae.
BMC Public Health 2014 14:1203.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
